OGG1 and acute myeloid leukemia: In acute myeloid leukemia (AML), OGG1 S326C was observed more frequently in patients experiencing relapse compared to other patients (28.9% vs. 8.9%, odds ratio = 4.10, 95% confidence interval = 1.35–12.70, p = 0.01), and those with the S326C variant exhibited a shorter relapse-free survival [92].